Sutezolid is in the same class of drugs as linezolid (oxazolidinones). Tests conducted over the past decade have indicated that sutezolid may have an improved therapeutic potential when compared to linezolid, which is currently recommended by the World Health Organization as a treatment option for drug-resistant forms of TB.

Sutezolid is currently being studied in three programs: 

• PAN-HM, in collaboration with The Aurum Institute
• PAN-TB, in collaboration with Gates MRI, Janssen, and Otsuka
• RAD-TB, in collaboration with ACTG

TB Alliance is committed to making sutezolid data and drug material available to the research community. For more information, please visit tballiance.org/SIRC.